| A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors (NCT06934616) | Genor Biopharma Co., Ltd. | 2025-04-24 |
| An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function (NCT06962774) | Alumis Inc | 2025-04-23 |
| Brain Signal Training to Enhance Affect Down-regulation (NCT06626789) | Central Institute of Mental Health, Mannheim | 2025-04-23 |
| A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function (NCT06916078) | Eli Lilly and Company | 2025-04-23 |
| A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) (NCT06894771) | Merck Sharp & Dohme LLC | 2025-04-23 |
| A Study to Evaluate the Safety, Tolerability and Dose-Response Relationship of HRS-9190 in Healthy Subjects (NCT06932315) | Jiangsu HengRui Medicine Co., Ltd. | 2025-04-23 |
| Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery (NCT06747390) | Ryan Carey | 2025-04-23 |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma (NCT06232044) | Alliance for Clinical Trials in Oncology | 2025-04-23 |
| Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma (NCT06829771) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-04-23 |
| Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure (NCT06831825) | Medley Therapeutics | 2025-04-23 |
| TREAD: Time Restricted Eating Intervention for Alzheimer's Disease (NCT06548191) | University of California, San Diego | 2025-04-23 |
| A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants (NCT06948006) | AstraZeneca | 2025-04-23 |
| A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer (NCT06827236) | BioNTech SE | 2025-04-23 |
| A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes (NCT06945419) | Eli Lilly and Company | 2025-04-23 |
| A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity (NCT06942923) | AstraZeneca | 2025-04-22 |
| Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis (NCT06704269) | Novartis Pharmaceuticals | 2025-04-22 |
| Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT07117760) | First Affiliated Hospital of Fujian Medical University | 2025-04-22 |
| A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors (NCT06669975) | AP Biosciences Inc. | 2025-04-22 |
| A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV (NCT06970223) | ViiV Healthcare | 2025-04-22 |
| A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women (NCT06908707) | Laekna Limited | 2025-04-22 |
| A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors (NCT07172802) | GI Innovation, Inc. | 2025-04-22 |
| Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD). (NCT06737354) | InnoVec Biotherapeutics Inc. | 2025-04-22 |
| Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy (NCT06902896) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2025-04-22 |
| UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy (NCT06047886) | University of Alabama at Birmingham | 2025-04-22 |
| A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients (NCT06879717) | iOnctura | 2025-04-22 |
| A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer (NCT06800339) | University of Maryland, Baltimore | 2025-04-22 |
| Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma (NCT06987916) | Shanghai Tongji Hospital, Tongji University School of Medicine | 2025-04-22 |
| A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults (NCT06935266) | Takeda | 2025-04-22 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects (NCT06485245) | Cascade Pharmaceuticals, Inc | 2025-04-22 |
| Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants (NCT06988423) | Crestone, Inc | 2025-04-21 |
| A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE (NCT06897930) | AstraZeneca | 2025-04-21 |
| A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A (NCT06916130) | Addpharma Inc. | 2025-04-21 |
| Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors (NCT07053904) | PharmaEssentia | 2025-04-21 |
| A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight (NCT06916091) | Eli Lilly and Company | 2025-04-21 |
| A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants (NCT06937619) | AbbVie | 2025-04-21 |
| Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (NCT06796361) | University Hospital, Basel, Switzerland | 2025-04-21 |
| Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05994157) | Y-mAbs Therapeutics | 2025-04-21 |
| a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors (NCT06878612) | Xingchen Peng | 2025-04-21 |
| Umbilical Cord Mesenchymal Stem Cell Secretome in Severe Erectile Dysfunction Non-responsive to Sildenafil (NCT06839651) | Indonesia University | 2025-04-21 |
| Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects (NCT06855147) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-04-21 |
| Multiple Ascending Dose Phase 1 Study of ALA-3000 (NCT06965569) | Alar Pharmaceuticals Inc. | 2025-04-21 |
| A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors (NCT06816108) | Ono Pharmaceutical Co., Ltd. | 2025-04-21 |
| In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial (NCT06704191) | Mayo Clinic | 2025-04-21 |
| An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa (NCT06936787) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2025-04-20 |
| R-MVST Cells for Treatment of Viral Infections in Children and Young Adults (NCT06926894) | Monica Bhatia | 2025-04-20 |
| Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases (NCT07134153) | Fudan University | 2025-04-18 |
| A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function (NCT06938529) | Vincentage Pharma Co., Ltd | 2025-04-18 |
| Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma (NCT06911255) | Yoon Jun Kim | 2025-04-18 |
| A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants (NCT07566130) | AbbVie | 2025-04-18 |
| A Study to Assess Safety, Tolerability and Exposure of 4ET1103 in Healthy Human Volunteers (NCT07586514) | 4E Therapeutics | 2025-04-18 |
| Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer (NCT06654037) | National Cancer Institute (NCI) | 2025-04-18 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide (NCT06972992) | Ascletis Pharma (China) Co., Limited | 2025-04-18 |
| A Study of MT-4561 in Patients With Various Advanced Solid Tumors (NCT06943521) | Tanabe Pharma America, Inc. | 2025-04-18 |
| IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors (NCT06974812) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-04-18 |
| Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer (NCT05672095) | City of Hope Medical Center | 2025-04-18 |
| CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH (NCT06947460) | Beijing GoBroad Hospital | 2025-04-18 |
| GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies (NCT06948981) | Grit Biotechnology | 2025-04-18 |
| Psilocybin Brain Stimulation and Imaging Pilot Study (NCT06835699) | Johns Hopkins University | 2025-04-18 |
| Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma (NCT06730542) | Juan P. Alderuccio, MD | 2025-04-17 |
| A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI (NCT07543744) | R-Pharm | 2025-04-17 |
| The Effect of AMG 133 on Gastric Emptying (NCT07429032) | Amgen | 2025-04-17 |
| Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older (NCT06907511) | Sanofi | 2025-04-17 |
| Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone (NCT05299398) | Verinder Sharma | 2025-04-17 |
| Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD) (NCT06945458) | Kymera Therapeutics, Inc. | 2025-04-17 |
| A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies (NCT07347171) | Cullgen (Shanghai),Inc | 2025-04-17 |
| A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants (NCT06925854) | AstraZeneca | 2025-04-17 |
| Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer (NCT06819228) | Vanderbilt-Ingram Cancer Center | 2025-04-17 |
| Bioequivalence Study betweenYHP2407 and YHR2502 in Healthy Subjects (NCT06926387) | Yuhan Corporation | 2025-04-17 |
| A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer (NCT06878248) | Calibr, a division of Scripps Research | 2025-04-17 |
| Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation (NCT06945614) | General Biophysics LLC | 2025-04-16 |
| A Study of HS-20094 in Overweight or Obese Participants (NCT07057674) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-04-16 |
| Peritoneal Ultrafiltration in Cardio Renal Syndrome. (NCT03994874) | Iperboreal Pharma Srl | 2025-04-16 |
| A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations (NCT07597668) | R-Pharm | 2025-04-16 |
| A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus (NCT06943937) | China Immunotech (Beijing) Biotechnology Co., Ltd. | 2025-04-16 |
| A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus (NCT06429800) | Atara Biotherapeutics | 2025-04-16 |
| A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer (NCT06840548) | Philogen S.p.A. | 2025-04-16 |
| Comparing Nebulized Ketamine,Nebulized Ketamine and Precedex and IM Ketamine for Analgesia in Pediatric Burn (NCT07086690) | Ain Shams University | 2025-04-16 |
| A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009) (NCT06580587) | Merck Sharp & Dohme LLC | 2025-04-15 |
| Phase Ib Clinical Study to Evaluate the Safety and Tolerability of VSA012 Injection in Paroxysmal Nocturnal Hemoglobinuria (NCT06848296) | Bisirna Therapeutics Pte. Ltd. | 2025-04-15 |
| Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients (NCT06903559) | Mansoura University | 2025-04-15 |
| E-cigarette Harm Reduction Among PLWHA in South Africa (NCT06169813) | NYU Langone Health | 2025-04-15 |
| STARLITE for Unresectable High-Grade Gliomas (NCT06428045) | University of Miami | 2025-04-15 |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (NCT06843447) | Merck Sharp & Dohme LLC | 2025-04-15 |
| Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) (NCT07193953) | Sunnybrook Health Sciences Centre | 2025-04-15 |
| Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's Disease (NCT06585384) | Fondation Ophtalmologique Adolphe de Rothschild | 2025-04-15 |
| Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors (NCT06795412) | Pyxis Oncology, Inc | 2025-04-15 |
| Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function (NCT07076030) | Zealand Pharma | 2025-04-15 |
| Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients (NCT06917950) | Mansoura University | 2025-04-15 |
| A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa (NCT06932003) | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 2025-04-15 |
| A Study of HS-20122 in Patients With Advanced Solid Tumors (NCT06927570) | Hansoh BioMedical R&D Company | 2025-04-15 |
| Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer (NCT06094842) | Fred Hutchinson Cancer Center | 2025-04-15 |
| The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects (NCT06872866) | Aspargo Labs, Inc | 2025-04-15 |
| Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older (NCT06904222) | Guangzhou Patronus Biotech Co., Ltd. | 2025-04-15 |
| Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial (NCT06919380) | Li Shiyue | 2025-04-15 |
| Pentoxifylline for Vascular Calcification in Kidney Disease (NCT06903689) | Mansoura University | 2025-04-15 |
| A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis (NCT06931990) | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 2025-04-15 |
| 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors (NCT06926998) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2025-04-15 |
| Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors (NCT06941766) | Peking Union Medical College Hospital | 2025-04-15 |
| PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) (NCT06673017) | PanTher Therapeutics | 2025-04-14 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) (NCT06858813) | AbbVie | 2025-04-14 |